|
Powered by Cell Signaling Technology |
Site Information |
---|
kLMkAFEsLksFQQQ SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 10206805 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Putative in vivo kinases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on Huntingtin: | |
Effects of modification on biological processes: |
Disease / Diagnostics Relevance | |
---|---|
Relevant diseases: |
References | |
---|---|
Cariulo C, et al. (2019) Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13. Biochem Biophys Res Commun
31677786 Curated Info |
|
Ochaba J, et al. (2019) IKKβ slows Huntington's disease progression in R6/1 mice. Proc Natl Acad Sci U S A 116, 10952-10961
31088970 Curated Info |
|
Di Pardo A, et al. (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 23, 2251-65
24301680 Curated Info |
|
Jia H, Kast RJ, Steffan JS, Thomas EA (2012) Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 21, 5280-93
22965876 Curated Info |